AccentHealth buys Havas point-of-care unit, doubles footprint

Share this article:
AccentHealth buys Havas point-of-care unit, doubles footprint
AccentHealth buys Havas point-of-care unit, doubles footprint

AccentHealth is acquiring Havas Impact, the holding company's waiting room "WallBoards" arm, in a move that will double the New York firm's footprint.

The Havas unit boasts a network of 20,000 physician offices that host its WallBoards (AccentHealth uses the term “Health Panels”), displays stocked with brochures offering condition-specific health information. AccentHealth's pre-acquisition network spanned 12,300 offices, some of which hosted the shop's Health Panels, others its waiting room TV network featuring CNN-branded content hosted by Dr. Sanjay Gupta. There was “minimal crossover” between the AccentHealth and Havas Networks, said VP marketing and communications Andrew Schulman.

“We've been working to double our national footprint, and with this acquisition, we're going to answer that call on reach and scale,” said Schulman.

The company's network will now extend to 26,000 offices, with around 12,500 hosting AccentHealth TV screens, and 63,000 physicians—up from 44,000.

It's not yet clear how many staff will make the jump from Havas to AccentHealth, but there will be “some collateral transition,” said Schulman. Where Havas Impact was headquartered in Chicago, with operations handled out of Atlanta, staffs will be consolidated into AccentHealth's offices, with sales in New York and operations in Tampa.

Going forward, the company is looking to add to its 17 condition-specific waiting room TV networks, launched last year, and to expand out of waiting rooms into other environments, including hospitals and fitness centers.

“It's a growth opportunity for our waiting room TV network,” said Schulman. “Our goal is to expand the waiting room experience and be able to fully brand all of our waiting rooms.”

Terms of the deal were not disclosed.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...